Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide. Open. Download Table | Schema for CALGB trial CALGB trial schema from publication: Small Cell Lung Cancer: Have We Made Any Progress Over the . This randomized phase III trial is comparing three different chest radiation therapy regimens to see how well they work in treating patients with limited-stage .

Author: Shakalkis Fenrikinos
Country: Brazil
Language: English (Spanish)
Genre: Business
Published (Last): 2 March 2011
Pages: 318
PDF File Size: 6.68 Mb
ePub File Size: 10.75 Mb
ISBN: 650-7-63174-837-1
Downloads: 3907
Price: Free* [*Free Regsitration Required]
Uploader: Voodoora

A total of 25 patients in the twice-daily radiation cwlgb group and 32 in the once-daily radiation therapy group did not get concurrent chemoradiation therapy.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

Adverse events were not significantly different between the two groups as well, with the exception of more neutropenia in patients treated with twice-daily radiation therapy. It was challenging to accrue patients with this disease. Radiation-related toxicities were lower than expected likely due to the use of modern RT techniques These inconclusive results suggest that either schedule can be used in this setting.

  DISCONTINUIDAD REMOVIBLE PDF

The clagb enrolled patients with histologically or cytologically proven SCLC recruited from 73 capgb in 7 European countries and Canada between and All analyses dalgb done on an intention-to-treat basis. Updated Trial Findings View More. Median overall survival was 30 months vs 25 months, a difference that is not statistically significant. Clinical Applications of Genomic Studies R.

High-dose radiation therapy to the lungs and esophagus in the once-daily arm did not seem to translate to a significant difference between the arms in terms of esophagitis or pneumonitis.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

No statistically significant differences between the two groups were reported for the rates of progression-free survival or local or metastatic disease progression. It evaluated the optimization of chemoradiotherapy in limited-stage SCLC.

Taofeek Kunle Owonikoko, MD. Formal discussant Taofeek Kunle Owonikoko, MDof Winship Cancer Institute of Emory University, Atlanta, said it has been controversial whether to use once-daily or twice-daily radiation therapy in this patient population. Expert Point of View: Seidman, MD, and Charles E.

  AVANT SAP1024B PDF

Patients with any response were offered prophylactic cranial radiation therapy. An international randomised trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer and good performance status.

There was one death in the twice-daily group and two in the once-daily group due to radiation pneumonitis. There was no statistically significant overall survival difference between the groups. In this trial, survival was higher than previously reported in other trials of this patient population, and radiation toxicities were lower than expected. Survival in both arms was higher than previously reported. By Alice Goodman June 25, Advertisement.

Eighty percent of patients had stage III disease.